Kinaxo enters into agreement with Takeda

Under the agreement, Kinaxo will make its KinaTor technology available to Takeda researchers involved in drug discovery, preclinical research and clinical development. Kinaxo’s cellular target profiling utilizes proprietary chemical proteomics technologies combined with state-of-the-art mass spectrometry to identify and characterize a drug candidate’s native molecular targets in cell lines and tissue samples.

Andreas Jenne, the CEO of Kinaxo, said: “We consider this agreement with Takeda, the leading R&D-oriented pharmaceutical company of Japan, to be a major progress in the world-wide expansion of our business. We continue to demonstrate the validation of the KinaTor technology by providing services to leading pharmaceutical and biotechnology companies, including Johnson& Johnson, Bayer-Schering, Takeda and UCB Pharma.”